Morgan Stanley lowered the target price for Sh Pharma (02607) to HKD17 from HKD18.4 and maintained the "overweight" rating.
The research house said following 3Q24, it cuts 2024-30e earnings by 3-9% on lower sales.
24/12/2024 15:21
{I-bank focus}Morgan lowers Sh Pharma (02607) to HKD17
Next︰24/12/2024 14:34 {I-bank focus}Morgan lowers Baiyunshan Ph (00874) to HKD21.4
23/12/2024 15:55 {I-bank focus}CMB raises Hansoh Pharma (03692) to HKD25.24
23/12/2024 15:14 {I-bank focus}CCB lowers Shenzhou Intl (02313) to HKD83
20/12/2024 15:52 {I-bank focus}BOCI raises WB (09898) to HKD79
20/12/2024 15:16 {I-bank focus}UBS lowers Zoomlion (01157) to HKD6.1
20/12/2024 14:41 {I-bank focus}Daiwa upgrades CKI Holdings (01038) to "buy"
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
